2026 Pediatric Rheumatology Symposium

March 18-21, 2026. Minneapolis, MN.

View by Number View by Title View Sessions

Jump to: View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z

Abstract Number: 015

Obinutuzumab Induces Histologic Remission And Deep Kidney Parenchymal B-Cell Depletion In Patients With Lupus Nephritis: Exploratory Analyses From The REGENCY Trial
Abstract Number: 037

Off-the-Shelf Anti-CD19 CAR T-cell Therapy with Reduced or No Conditioning Chemotherapy Demonstrates Efficacy and Tolerability in Systemic Lupus Erythematosus: Meaningful Activity Supports Planned Adolescent Enrollment
Abstract Number: 082

Ophthalmic Predictors of Response to Methotrexate Monotherapy in Pediatric Non-Infectious Uveitis
Abstract Number: 029

Oral vs Subcutaneous Methotrexate at High Dose for Pediatric Anterior Uveitis
Abstract Number: 085

Outcomes of Oligoarticular Juvenile Idiopathic Arthritis Patients Treated with Intra-articular Glucocorticoids: Can We Predict Successful Treatment?

Jump to: View All • a b c d e f g h i j k l m n [o] p q r s t u v w x y z

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

2026 Pediatric Rheumatology Symposium

Obinutuzumab Induces Histologic Remission And Deep Kidney Parenchymal B-Cell Depletion In Patients With Lupus Nephritis: Exploratory Analyses From The REGENCY Trial

Off-the-Shelf Anti-CD19 CAR T-cell Therapy with Reduced or No Conditioning Chemotherapy Demonstrates Efficacy and Tolerability in Systemic Lupus Erythematosus: Meaningful Activity Supports Planned Adolescent Enrollment

Ophthalmic Predictors of Response to Methotrexate Monotherapy in Pediatric Non-Infectious Uveitis

Oral vs Subcutaneous Methotrexate at High Dose for Pediatric Anterior Uveitis

Outcomes of Oligoarticular Juvenile Idiopathic Arthritis Patients Treated with Intra-articular Glucocorticoids: Can We Predict Successful Treatment?